Latest filing published 25 Mar 2026 for Ovid Therapeutics Inc., €57k.
Filing timeline
BuySaleInsider track record
Closed purchases
Based on 5 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Purchases by company
Since each purchase
- -86.1%Entry US$3.05 · Close at T+365 US$0.43
- -37.1%Entry US$5.69 · Close at T+365 US$3.58
- +141.9%Entry US$2.29 · Close at T+365 US$5.54
- +51.5%Entry US$2.06 · Close at T+365 US$3.12
- -24.5%Entry US$8.71 · Close at T+365 US$6.57
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Jeremy M. Levin: trading record in brief
Jeremy M. Levin is a declared insider at 2 companies; the most frequent names are Bristol Myers Squibb Co and Ovid Therapeutics Inc. The record holds 28 filings, for trades running from 1 October 2010 to 23 March 2026.
On the market, this insider has only ever bought: 5 purchases, €450k in total. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. The rest of the record consists of 9 share grants and 7 option exercises.
The median purchase comes to €93k. The 5 purchases reviewed show no overlap with other insiders buying the same stock within a month. After 5 purchases with a full 90-day history, the hit rate stands at 60% and the median 90-day move at +16.9%. Past outcomes like these are no guarantee of what comes next.
On 25 March 2026 came the latest disclosure, an option exercise for €57k in Ovid Therapeutics Inc. The most recent open-market purchase was published on 20 March 2024, 964 days ago. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. The legal deadline for a Form 4 is two business days after the transaction. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Companies and markets linked to Jeremy M. Levin
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 47,333 shares@ US$1.4055.3% of flowCommon StockSEC:0001256153-26-000004:0
- 71,000 sharesCommon StockSEC:0001256153-25-000004:0
- 18,248 shares@ US$2.7644.7% of flowCommon StockSEC:0001209191-24-005001:0Canonical exit: 16 Jun 2024 (T+90)
- 465,116 shares0Common StockSEC:0001415889-24-003721:0
- 573,275 shares0Common StockSEC:0001209191-23-057640:1
- 573,275 shares0Common StockSEC:0001209191-23-057640:0
- 8,488 shares@ US$5.8414.9% of flowCommon StockSEC:0001209191-20-049011:0Canonical exit: 26 Nov 2020 (T+90)
- 60,000 shares@ US$2.5033.0% of flowCommon StockSEC:0001209191-19-052988:0Canonical exit: 6 Jan 2020 (T+90)
- 75,000 shares@ US$2.0031.9% of flowCommon StockSEC:0001209191-19-013905:0Canonical exit: 23 May 2019 (T+90)
- 15,334 shares@ US$7.1518.3% of flowCommon StockSEC:0001209191-17-050467:0Canonical exit: 23 Nov 2017 (T+90)
- 400,150 sharesCommon StockSEC:0001209191-17-031376:0
- 35,461 sharesCommon StockSEC:0001209191-17-031376:1
- 10,000 shares0Common Stock, $0.10 par valueSEC:0001225208-11-022950:0
- 4,704 shares@ US$31.38Common Stock, $0.10 par valueSEC:0001225208-11-022950:1
- 2,324 shares@ US$25.58Common Stock, $0.10 par valueSEC:0001225208-11-009853:0
- 2,916 shares@ US$25.58Common Stock, $0.10 par valueSEC:0001225208-11-009853:1
- 1,397 shares0Common Stock, $0.10 par valueSEC:0001225208-11-009158:0
- 566 shares@ US$26.43Common Stock, $0.10 par valueSEC:0001225208-11-009158:1
- 2,307 shares0Common Stock, $0.10 par valueSEC:0001225208-11-008911:0
- 84 shares0Common Stock, $0.10 par valueSEC:0001225208-11-008911:1
- 968 shares@ US$25.39Common Stock, $0.10 par valueSEC:0001225208-11-008911:2
- 2,019 shares0Common Stock, $0.10 par valueSEC:0001225208-11-008911:3
- 818 shares@ US$26.14Common Stock, $0.10 par valueSEC:0001225208-11-008911:4
- 12,944 shares0Common Stock, $0.10 par valueSEC:0001225208-11-008706:0
- 2,324 shares0Common Stock, $0.10 par valueSEC:0001225208-11-008706:1
25 of 28 declarations
